Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial

F.W. Hamilton\textsuperscript{a,b,*}, Todd Lee\textsuperscript{c}, D.T. Arnold\textsuperscript{d}, R. Lilford\textsuperscript{e}, K. Hemming\textsuperscript{e}

\textsuperscript{a} MRC-IEU Integrative Epidemiology Unit, University of Bristol, Bristol, UK
\textsuperscript{b} Infection Science, North Bristol NHS Trust, Bristol, UK
\textsuperscript{c} Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Canada
\textsuperscript{d} Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK
\textsuperscript{e} Institute of Applied Health Research, University of Birmingham, Birmingham, UK

\section{Introduction}

Convalescent plasma (CP) – blood components from patients who have recovered from an infection – has been used for more than a century to treat infections, with widespread use in the 1920s and 1930s for pneumococcal infections and scarlet fever, before falling out of favour with the development of antibiotics (The Lancet Haematology, 2020). The principle is that of `passive immunization’, i.e., passing antibodies from those who have recovered from the infection to those naïve to it, thereby provid-

\footnote{Corresponding author: Fergus Hamilton, MRC-IEU Integrative Epidemiology Unit, University of Bristol, Bristol, UK. E-mail address: Fergus.hamilton@bristol.ac.uk (F.W. Hamilton).}

\begin{figure}
  \centering
  \includegraphics[width=\textwidth]{figure1.png}
  \caption{A graph illustrating the comparison of convalescent plasma with placebo.}
  \label{fig:comparison}
\end{figure}

ing a degree of protection from that specific agent (Keller and Stiehm, 2000). It is therefore unsurprising that interest in the use of CP to prevent and treat coronavirus disease 2019 (COVID-19) has been widespread (The Lancet Haematology, 2020). Unfortunately, despite best efforts, most of this usage has occurred outside of randomized controlled trials (RCT), with >100 000 doses given in the United States alone (FDA, 2021).

Fortunately, the RECOVERY collaborative group have recently reported the largest RCT of CP in hospitalized patients with COVID-19 (The RECOVERY Collaborative Group et al., 2021). The authors concluded that CP provided no benefit, with the observed mortality equal in both arms: 1399 (24\%) of 5795 patients allocated to CP and 1408 (24\%) of 5763 patients allocated to usual care died within 28 days (rate ratio (RR) 1.00, 95\% confidence interval (CI) 0.93–1.07; \(P = 0.95\)). They also concluded that there was no dif-

\begin{table}
  \centering
  \begin{tabular}{|c|c|c|c|}
    \hline
    Treatment & Control & RR & P-value \\
    \hline
    CP & Placebo & 1.00 & 0.95 \\
    \hline
  \end{tabular}
  \caption{Comparison of convalescent plasma with placebo.}
  \label{tab:comparison}
\end{table}

\section{Conclusion}

The results of the RECOVERY trial suggest that CP is not effective in treating COVID-19. However, further research is needed to determine the optimal use of CP in the treatment of other infections and to optimize the selection of patients for CP therapy.

\section{Methods}

The RECOVERY trial was a randomized controlled trial (RCT) conducted in the United Kingdom. Patients admitted to hospital with COVID-19 were randomly assigned to receive CP or placebo. The primary outcome was all-cause mortality at 28 days. The study was terminated early due to a lack of benefit of CP.

\section{Discussion}

The findings of the RECOVERY trial have implications for the future use of CP in the treatment of infectious diseases. Further research is needed to determine the optimal use of CP in the treatment of other infections and to optimize the selection of patients for CP therapy.

\section{Acknowledgments}

The authors would like to thank the RECOVERY collaborative group for their contributions to this work. This research was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Infection and Public Health (HPA/C) at the London School of Hygiene & Tropical Medicine.

\section{References}


ference across pre-specified subgroups, including those with detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests at the time of randomization (seropositive group) (19% versus 18%; RR 1.06, 95% CI 0.94–1.19) and seronegative patients (32% versus 34%; RR 0.96, 95% CI 0.85–1.07), with test for interaction $P = 0.23$. In particular, they noted, on the advice of the Drug Safety and Monitoring Committee (DMC), that: “there was no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit either overall or in any pre-specified subgroup”. In the United Kingdom, the data have been taken by the regulator as strong evidence of a null effect, leading the Medicines Health Regulatory Authority (MHRA (CAS-ViewAlert 2021); the UK medicines regulator) to recommend against the use of CP in patients hospitalized with COVID-19, effectively removing the therapy in the National Health Service (NHS), with many editorialists agreeing with the authors that this proves no effect (Liu and Aberg, 2021).

Before accepting that CP is ineffective in hospitalized patients, it is important to recognize the clear distinction between patients who are likely to benefit and those who are not. The therapeu- tic mechanism of CP and monoclonal antibody (e.g., REGN-COV2) treatments is passive immunization – the gifting of antibodies. These antibodies (donated by recovered patients) develop in most people by 7–10 days, as part of the normal immune response. It is not surprising to think that the greatest (or any) benefit of CP would only occur in patients who present early or are seronegative, or conversely, that there will be little to no benefit in giving antibodies to those who already have antibodies or have de- veloped their own immune response. The previous literature on severe acute respiratory syndrome (SARS) supports this distinction (Cheng et al., 2005; Yeh et al., 2005), as well as data clearly identifying a protective effect of monoclonal antibodies (manufactured antibodies, rather than donated) in early COVID-19 trials, with much weaker effects in hospitalized patients later in the disease course (ACTIV-3/TICO LY-CoV555 Study Group et al., 2021; Chen et al., 2021; O’Hare, 2021; Weinreich et al., 2021). Immuno- logical data and cases of persistent infection show that failure of an early antibody response is associated with both severe disease and, in patients without any antibodies, the risk of persistent disease (Kemp et al., 2021; Sette and Crotty 2021). Others have also argued that seropositivity is a reason for failure of CP (Bajpai et al., 2020).

On that background, it is logical to analyse the data from patients who are seronegative (hypothesized more likely to benefit) separately from those who are seropositive (hypothesized less likely to benefit). Likewise, it is rational to analyse the data by time from symptom onset, given that the only positive trial of CP occurred with treatment given within 72 hours (Libster et al., 2021).

Although subgroup analyses can be complicated by chance im- balances, lower power, and issues of multiple testing, they are ap- propriate to generate hypotheses and could be used in support of the argument of not disregarding CP as a potential treatment too soon (Jones et al., 2011; Lee et al., 2021). Moreover, conflating ab- sence of evidence for a small effect with evidence of no effect fur- ther risks discarding a therapy that could still have a meaningful benefit. It was therefore sought to undertake a Bayesian re-analysis to estimate the probability of (a) any benefit, (b) a small benefit (defined here as equivalent to a number needed to treat (NNT) of at most 200), and (c) a modest benefit (equivalent of a NNT of at most 100) for all patients and for both subgroups specified above.

2. Methods

The intention-to-treat results from the RECOVERY trial were ex- tracted, both overall and for pre-specified subgroups: seronegative, seropositive, ≤7 days since symptom onset, and >7 days since symptom onset. These two subgroups (antibody status and time from onset) were selected on the basis of the scientific justification described above. No granular data were available to combine these two subcategories.

The ’Bayes’ function Stata version 16 (StataCorp, College Station, TX, USA) was used to calculate posterior probabilities. The proba- bilities of (a) any benefit (Odds Ratio, OR <1), (b) a small but ar- guably clinically important benefit, estimated as an absolute risk difference of at least 0.5% (Number Needed to Treat,NNT ≤200), and (c) a modest benefit, which was defined here as a risk differ- ence of at least 1% (NNT ≤100) were calculated. These risk differ- ences were chosen after internal discussion between the study au- thors regarding what would be considered an important effect size considering the complexity and challenges in using CP. By nature, they are subjective, but reflect effect sizes that might be salient to patients, their families, and clinicians.

As suggested by a recent review on Bayesian re-analysis in COVID-19 (Zampieri et al., 2021), four probability assumptions were chosen to account for varying prior views: (1) vague (no in- formation; mean risk difference (RD) 0, standard deviation (SD) 10 000); (2) optimistic (10% risk of harm; mean RD 0.01, SD 0.007); (3) sceptical (tightly around the null; mean RD 0, SD 0.007); (4) pessimistic (10% chance of benefit; mean RD −0.005, SD 0.0036). Posterior probabilities were computed from binomial regression models. Posterior density function graphs were produced for each prior assumption.

All code used to generate these figures is available in the Supplementary Material.

3. Results

Table 1 presents the posterior probabilities of benefit for each prior.

Across the whole trial population, the estimated chance of any benefit was found to be around 65%, with little difference across all prior assumptions. The posterior probability of a modest benefit (preferring treatment arm) was found to be around 19% across all prior assumptions. The associated posterior density functions are available in the Supplementary Material, as supplementary fig- ures.

In the seronegative subgroup, the estimated likelihood of any benefit was greater, at around 90%, across all prior assumptions. The estimated chance of a risk difference (modest benefit) of >1% was also high (more than 66% across all three priors), and varied little between prior assumptions. This contrasts with the seroposi- tive arm, where the estimated chance of any benefit was only 20%, and with a very small (3%) chance of a modest benefit (NNT ≤100).

These results are mirrored in the early treatment subgroup, with an around 95% chance of benefit in patients treated within 7 days of symptom onset. The chance of a modest benefit (NNT ≤100) was about 80% across all prior assumptions. However, in pa- tients who presented after 7 days, the chance of CP providing any benefit was small (17%), with a very low chance (≈2%) of a modest benefit (NNT ≤100).

4. Discussion

The RECOVERY trial has been a paradigm for a rapid pragmatic approach to trialling new therapies in a pandemic. Good practice requires a firm pre-specified analysis plan with a clear pre-defined subgroup analysis (Schulz et al., 2010). However, the conclusions drawn by the RECOVERY collaborative group and the MHRA with respect to CP risks conflating absence of evidence of a small effect with evidence that there is no benefit. Re-analysis of the original data using Bayesian methods yielded a small probability (~15%) of an effect with an NNT of 100 across the whole trial, with even
higher probabilities of 90% and 75%, respectively, in patients presenting within 7 days of symptoms and patients antibody-negative on presentation.

Patients in the population who presented early were easy to identify (from history alone) and constituted more than a third of the whole trial population. The estimated chance of a benefit with a NNT of 100 changed from ~7% in those presenting late to ~90% in those presenting early.

Many clinicians, patients, and their families might consider benefits in the region of one life saved for every 100 or 200 people treated as meaningful benefits. From a societal perspective, the treatment would need to achieve a mean of only one quality-adjusted life year to justify a £20 000 treatment cost. However, it is not our intention to prove that CP is a cost-effective treatment – at heart that is a value judgement. We wish only to show that the conclusion that the treatment is ineffective is unlikely to be true for people who have not developed immunity at the point where the therapeutic decision is made. It is always important to consider the literature in the round when making policy recommendations.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>Vague prior</th>
<th>Optimistic prior</th>
<th>Sceptical prior</th>
<th>Pessimistic prior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole trial (n = 11 558)</td>
<td>64%</td>
<td>65%</td>
<td>64%</td>
<td>62%</td>
</tr>
<tr>
<td>Any benefit</td>
<td>64%</td>
<td>65%</td>
<td>64%</td>
<td>62%</td>
</tr>
<tr>
<td>Small benefit</td>
<td>43%</td>
<td>41%</td>
<td>40%</td>
<td>38%</td>
</tr>
<tr>
<td>Modest benefit</td>
<td>20%</td>
<td>19%</td>
<td>19%</td>
<td>18%</td>
</tr>
<tr>
<td>Seronegative subgroup (n = 3676)</td>
<td>66%</td>
<td>68%</td>
<td>66%</td>
<td>67%</td>
</tr>
<tr>
<td>Any benefit</td>
<td>86%</td>
<td>87%</td>
<td>86%</td>
<td>86%</td>
</tr>
<tr>
<td>Small benefit</td>
<td>79%</td>
<td>78%</td>
<td>77%</td>
<td>78%</td>
</tr>
<tr>
<td>Modest benefit</td>
<td>68%</td>
<td>68%</td>
<td>66%</td>
<td>67%</td>
</tr>
<tr>
<td>Seropositive subgroup (n = 5888)</td>
<td>20%</td>
<td>23%</td>
<td>21%</td>
<td>21%</td>
</tr>
<tr>
<td>Any benefit</td>
<td>9%</td>
<td>11%</td>
<td>11%</td>
<td>10%</td>
</tr>
<tr>
<td>Small benefit</td>
<td>3%</td>
<td>4%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>≥7 days since symptom onset (n = 4466)</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
</tr>
<tr>
<td>Any benefit</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>Small benefit</td>
<td>80%</td>
<td>82%</td>
<td>82%</td>
<td>80%</td>
</tr>
<tr>
<td>Modest benefit</td>
<td>17%</td>
<td>17%</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>≥7 days since symptom onset (n = 7086)</td>
<td>7%</td>
<td>8%</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>Any benefit</td>
<td>3%</td>
<td>3%</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Vague prior: N(0, SD = 10 000); optimistic prior: N(0.01, SD = 0.007); sceptical prior: N(0, SD = 0.007); pessimistic prior N(–0.01, SD = 0.0036). Small benefit defined as a risk difference >0.5% (equivalent to a NNT ≥200); Moderate benefit defined as a risk difference >1% (equivalent to a NNT ≤100). SD, standard deviation; NNT, number needed to treat.

Yet further support for our conclusion can be found from secondary outcomes in the RECOVERY trial that we would expect to correlate with the primary outcome if the hypothesis that CP is particularly effective in immunologically naïve patients. Both secondary outcomes in the original study, i.e., discharge home by day 28 and invasive mechanical ventilation or death, showed heterogeneity with respect to serological status and intervention effect, with impressive P-values of 0.008 and 0.01, respectively, in favour of CP. Although we have not focused on this to avoid accusations of ‘cherry picking’ the data, this is entirely consistent with and supportive of a causal path by which CP reduces mortality, and both of these are critical outcomes relevant to both patients and clinicians.

It is recognized that there may have been chance imbalances in age or comorbidity within the seronegative or early subgroup of patients, since randomization was not stratified on serological status or time from presentation (The RECOVERY Collaborative Group et al., 2021). However, they were pre-specified subgroups and made up a substantial proportion of all participants as stated above. It is also recognized that both of these groups double counted a number of patients for the reason given above. An alternative approach would have been to create four non-overlapping groups: both (serologically positive and late presentation), neither, and two other groups. However, these groups could not be constructed because we did not have the raw data. In any event, both serological negativity and early presentation tap into a shared pathway concerning the development of immunity, even if there are other pathways involved.

In conclusion, the RECOVERY trial for CP reported no benefit. Recognizing the changing literature since the trial started and using a variety of priors, we suggest the reporting of no effect may be premature. It remains plausible that CP has a small but clinically important effect on mortality in those who have not already developed an antibody response or who present early. It is clear that any effect is likely small, but we would argue that clinicians, scientists, and government agencies should review all trial data in totality, rather than regarding the null result as fixed.
Funding

No formal funding was used for this article, but FH’s time was covered by the GW4 CAT Wellcome Doctoral training scheme. R JL is funded by the NHRI ARC West Midlands. This research was funded in whole, or in part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Ethical approval

No formal ethical approval was required for this work, as it is was a re-analysis of published data.

Conflict of interest

None of the authors have any conflict of interest to declare.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijid.2021.06.034.

References

O’Hare R. Blood plasma treatment has limited effect for sickest COVID-19 patients; 2021 [Internet]. Available from: https://www.imperial.ac.uk/news/211403/blood-plasma-treatment-limited-effect-sickest/.